Analysts expect BioXcel Therapeutics Inc (NASDAQ:BTAI) to announce earnings per share of ($0.26) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for BioXcel Therapeutics’ earnings. The business is expected to issue its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that BioXcel Therapeutics will report full-year earnings of ($1.12) per share for the current year. For the next year, analysts forecast that the business will post earnings of ($1.94) per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Wednesday, August 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.13.

BTAI has been the topic of a number of analyst reports. Canaccord Genuity restated a “buy” rating and set a $21.00 target price on shares of BioXcel Therapeutics in a research note on Friday, August 10th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of BioXcel Therapeutics in a research note on Tuesday, June 12th. Finally, Zacks Investment Research upgraded shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, August 14th. Six investment analysts have rated the stock with a buy rating, BioXcel Therapeutics currently has an average rating of “Buy” and a consensus target price of $18.67.

BTAI opened at $9.88 on Wednesday. BioXcel Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $14.79.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. lifted its stake in shares of BioXcel Therapeutics by 10.7% during the 2nd quarter. Point72 Asset Management L.P. now owns 65,809 shares of the company’s stock valued at $605,000 after buying an additional 6,358 shares in the last quarter. BlackRock Inc. purchased a new stake in BioXcel Therapeutics in the 2nd quarter worth $137,000. Millennium Management LLC purchased a new stake in BioXcel Therapeutics in the 1st quarter worth $316,000. California Public Employees Retirement System purchased a new stake in BioXcel Therapeutics in the 1st quarter worth $3,362,000. Finally, Barclays PLC purchased a new stake in BioXcel Therapeutics in the 1st quarter worth $6,331,000. Institutional investors own 23.81% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

See Also: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.